Clinical study on Rosiglitazone improving vascular endothelial function in Type 2 diabetes

Objective To examine the influence of rosiglitazone on endothelial function.Methods Flow mediated dilation(FMD)was tested with high resolution ultrasound method and plasma C-reaction protein(CRP)level was also measured before and after Rosiglitazone therapy in 34 impaired glucose tolerance(IGT)patients.Results Level of FMD rate:(7.6±2.9)%(before rosiglitazone therapy)vs(14.9±6.1)%(after rosiglitazone therapy),there is significance difference between two groups(P0.01).The level of plasma CRP before rosiglitazone therapy was significantly lower than that of after 4 weeks rosiglitazone therapy:(7.6±3.1)mg/L vs(4.1±1.5)mg/L)(P0.01).Conclusion The use of rosiglitazone not only improve the endothelial dysfunction but also decrease the level of inflammation reaction in patients with IGT.